THERAPEUTIC DEVELOPMENT - DESFERRIOXAMINE TREATMENT REDUCES BLOOD-TRANSFUSION REQUIREMENTS IN PATIENTS WITH MYELODYSPLASTIC SYNDROME

被引：41

作者：

JENSEN, PD

JENSEN, IM

ELLEGAARD, J

机构：

[1] University Department of Medicine and Haematology, Aarhus Amtssygehus, Aarhus, DK-8000

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 1992年 / 80卷 / 01期

关键词：

D O I：

10.1111/j.1365-2141.1992.tb06411.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：121 / 124

页数：4

共 22 条

[1] LONG-TERM CHELATION THERAPY IN THALASSEMIA MAJOR - EFFECT ON LIVER IRON CONCENTRATION, LIVER HISTOLOGY, AND CLINICAL PROGRESS [J].

BARRY, M ;

FLYNN, DM ;

LETSKY, EA ;

RISDON, RA .

BMJ-BRITISH MEDICAL JOURNAL, 1974, 2 (5909) :16-20

[2]

Basile C, 1988, Nephrol Dial Transplant, V3, P355

[3] PROPOSALS FOR THE CLASSIFICATION OF THE MYELODYSPLASTIC SYNDROMES [J].

BENNETT, JM ;

CATOVSKY, D ;

DANIEL, MT ;

FLANDRIN, G ;

GALTON, DAG ;

GRALNICK, HR ;

SULTAN, C .

BRITISH JOURNAL OF HAEMATOLOGY, 1982, 51 (02) :189-199

[4] THE TREATMENT OF ANEMIA IN THE MYELODYSPLASTIC SYNDROMES WITH RECOMBINANT-HUMAN-ERYTHROPOIETIN [J].

BOWEN, D ;

CULLIGAN, D ;

JACOBS, A .

BRITISH JOURNAL OF HAEMATOLOGY, 1991, 77 (03) :419-423

[5]

CROPP GJA, 1978, J PEDIATR, V78, P220

[6]

Cuvelier R, 1988, Nephrol Dial Transplant, V3, P104

[7]

DELASERNA FJ, 1988, LANCET, V2, P1009

[8] THE USE OF CHELATING-AGENTS IN THE TREATMENT OF ALUMINUM OVERLOAD [J].

DOMINGO, JL .

JOURNAL OF TOXICOLOGY-CLINICAL TOXICOLOGY, 1989, 27 (06) :355-367

[9]

Felipe C, 1988, Nephrol Dial Transplant, V3, P105

[10]

GRANT AC, 1988, LANCET, V2, P1405

← 1 2 3 →